共 38 条
- [31] Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind StudyCNS Drugs, 2015, 29 : 331 - 340Sharon B. WigalEarl NordbrockAkwete L. AdjeiAnn ChildressRobert J. KupperLaurence Greenhill
- [32] A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity DisorderJOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2020, 30 (09) : 549 - 557Mattingly, GregArnold, ValerieYan, BrianYu, MingRobertson, Brigitte
- [33] Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot studyNutrition Journal, 12Mostafa AmrAhmed El-MogyTarek ShamsKaren VieiraShaheen E Lakhan
- [34] A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace designPOSTGRADUATE MEDICINE, 2018, 130 (05) : 481 - 493Wigal, TimothyBrams, MatthewFrick, GlenYan, BrianMadhoo, Manisha
- [35] Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled StudyJOURNAL OF ATTENTION DISORDERS, 2017, 21 (14) : 1198 - 1207Weisler, RichardGinsberg, LawrenceDirks, BryanDeas, PatrickAdeyi, BenAdler, Lenard A.
- [36] Improved Executive Function in Adults Diagnosed With Attention-Deficit/Hyperactivity Disorder as Measured by the Brown Attention-Deficit Disorder Scale Following Treatment With SHP465 Mixed Amphetamine Salts Extended-Release: Post Hoc Analyses From 2 Randomized, Placebo-Controlled StudiesJOURNAL OF ATTENTION DISORDERS, 2022, 26 (02) : 256 - 266Brown, Thomas E.Chen, JieRobertson, Brigitte
- [37] Long-Term (1 Year) Safety and Efficacy of Methylphenidate Modified-Release Long-Acting Formulation (MPH-LA) in Adults with Attention-Deficit Hyperactivity Disorder: A 26-Week, Flexible-Dose, Open-Label Extension to a 40-Week, Double-Blind, Randomised, Placebo-Controlled Core StudyCNS Drugs, 2014, 28 : 951 - 962Y. GinsbergT. ArngrimA. PhilipsenP. GandhiC.-W. ChenV. KumarM. Huss
- [38] Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label ExtensionJOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2021, 31 (09) : 610 - 622Weiss, Margaret D.Cutler, Andrew J.Kollins, Scott H.Donnelly, Graeme A. E.